MedTech
The German Pharma and MedTech Mittelstand: Sartorius, Draegerwerk, and the Post-COVID Opportunity Few sectors have endured a more disorienting demand cycle than pharmaceutical equipment and medical technology over the 2021-2025 period. The COVID-19 pandemic created a surge in demand for bioprocessing equipment, ventilators, and safety devices that bore little relationship
enterprise software
Enterprise Software Made in Germany: Why Nemetschek, SAP's Mid-Cap Rivals, and TeamViewer Deserve Attention When investors think of German enterprise software, SAP occupies the entire field of vision. The Walldorf giant — with revenues exceeding €35 billion and a cloud transition now fully underway — is a legitimate global technology
specialty chemicals
German Specialty Chemicals: The Hidden Margin Champions For institutional investors scanning European equities, the German specialty chemicals sector represents one of the most consistently undervalued pockets of quality. While headline narrative has fixated on German automotive malaise and the Energiewende cost burden, a cohort of chemical companies has quietly engineered
Sector Analysis
About the Author: Dirk Roethig is Managing Director at ALVEON Partners and founder of VERDANTIS Impact Capital. With 25+ years in European mid-cap markets, he provides institutional-grade analysis of German Hidden Champions.
Analysis
About the Author: Dirk Roethig is Managing Director at ALVEON Partners and founder of VERDANTIS Impact Capital. With 25+ years in European mid-cap markets, he provides institutional-grade analysis of German Hidden Champions.
Welcome
About the Author: Dirk Roethig is Managing Director at ALVEON Partners and founder of VERDANTIS Impact Capital. With 25+ years in European mid-cap markets, he provides institutional-grade analysis of German Hidden Champions.